On Monday, shareholders of pharmaceutical firm Celltrion Inc. and its sales and marketing affiliate Celltrion Healthcare Co. gave the go-ahead for the two companies to merge. This follows Celltrion’s announcement three months prior that it intended to unite the three listed firms — Celltrion, Celltrion Healthcare, and Celltrion Pharm Inc. — for the purpose of enhancing efficiency and expanding their drug portfolio.
The merger is slated to be finalized on December 28th, with the new company’s stock available for purchase on January 12th.
The logo of Celltrion Healthcare Co. captured from its official website (PHOTO NOT FOR SALE) (Yonhap)
nyway@yna.co.kr
(END)
Related Articles: Celltrion’s new autoimmune disease treatment wins FDA approval; Celltrion to hold vote on merger plan with Celltrion Healthcare next week